


Cempra, Inc. (Nasdaq: CEMP) is a clinical stage pharmaceutical company focused on developing well-differentiated antibiotics to treat bacterial infections in the hospital and community.

Solithera™ (solithromycin) – Next Generation Macrolide Antibiotic

Key features for potential broad use: excellent oral bioavailability, high stability in solution, demonstrated activity against azithromycin-resistant strains in vivo and in vitro

- **NDA/MAA submitted 2Q 2016 for solithromycin IV and oral for CABP, Dec 2016 PDUFA date**
- Phase 2/3 pivotal pediatric trial currently underway
- SOLITAIRE-U Phase 3 trial in gonorrhea and chlamydia initiated 3Q 2014
- Pediatric and biodefense development supported by up to \$60.2 million Biomedical Advanced Research and Development Authority (BARDA) contract
- Exclusive license and development agreement in Japan with Toyama Chemical Co. (FUJIFILM) – Successfully completed Phase 2 in community-acquired bacterial pneumonia (CABP)



Growing Critical Need in the Large CABP Treatment Market

- **CABP is the most frequently treated infectious disease in the U.S. with 5-10 million cases annually, including >1 million hospitalizations per year¹.**
- CABP causes more deaths per year than any other infection²
- Widespread resistance to community antibiotics causing greater numbers of hospitalizations and increased risk of serious secondary infections

TAKSTA™ (Oral Fusidic Acid) for Skin and for Bone and Joint Infections

Oral antibiotic with a long history of safety and efficacy outside the U.S. against acute bacterial skin and skin structure infections (ABSSSI), including MRSA, and bone and joint infections

- Development focused on staphylococcal skin and bone and joint infections
- Patented loading dose regimen minimizes resistance development and unique mechanism minimizes cross resistance with other drugs
- Demonstrated comparable efficacy to linezolid in Phase 2 trials in ABSSSI patients
- Candidate for long-term oral use

Executive Management

Prabhavathi Fernandes, Ph.D.
Founder, President, & CEO

Mark W. Hahn
Chief Financial Officer

David Moore
Chief Commercial Officer

David Oldach, M.D.
Chief Medical Officer

Munir Abdullah, Ph.D.
EVP, Regulatory Affairs

John Bluth
EVP, IR and Corp. Comm.

Richard Skow
VP, Legal and Compliance

Glenn S. Tillotson, Ph.D.
SVP, Medical Affairs

Financial Highlights

Cash (6/30/16): \$250.7m
Shares Out. (6/30/16): 50.7m

Corporate Headquarters

Building Two Quadrangle
6320 Quadrangle Drive, 3rd floor
Chapel Hill, NC 27517
(919) 576-2306
info@cempra.com

Clinical Development Pipeline

PRODUCT CANDIDATE	INDICATION	FORMULATION	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
SOLITHROMYCIN	Community Acquired Bacterial Pneumonia (CABP)	P3 Oral Completed			NDA/MAA submitted 2Q 2016	
		P3 IV-to-Oral Completed			NDA/MAA submitted 2Q 2016	
		Pediatric: Capsule/Suspension/IV				
	Biodefense Use	Oral/Suspension				
	Urethritis/Gonorrhea	Oral				
TAKSTA FUSIDIC ACID	Chronic Bone and Joint Infections	Oral				
	ABSSSI	Oral				
NON-ANTIBIOTIC MACROLIDE	Diabetic Gastroparesis and GERD					

1. File Jr TM, Marrie, TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med 2010; 122(2): 130-41
2. Freeman, MK. CABP: A Primer for Pharmacists: US Pharmacist July 1, 2013

Company Contact

John Bluth
EVP, IR and Corp. Comm.
(984) 209-4534
jbluth@cempra.com

Investor Inquiries

Robert H. Uhl
Westwicke Partners
(858) 356-5932
robert.uhl@westwicke.com

Media Inquiries

Melyssa Weible
Elixir Health PR
(201) 723-5805
mweible@elixirhealthpr.com

Analyst Coverage

- Ritu Baral**
Cowen & Company
- Kevin Kendra**
Gabelli & Company
- Debjit Chattopadhyay**
Janney Montgomery Scott
- Eun K. Yang, Ph.D.**
Jefferies & Co.
- Jessica Fye**
J.P. Morgan Securities
- Robert C. Hazlett**
Ladenburg Thalmann & Co.
- Andrew Berens, M.D.**
Morgan Stanley
- Alan Carr, Ph.D.**
Needham & Company
- Brian P. Skorney**
Robert W. Baird & Co.
- Michael Higgins**
Roth Capital Partners
- Stephen Willey**
Stifel Nicolaus
- Edward Nash**
SunTrust
- Stephen Brozak**
WBB Securities